**Alternative Commercial Proposal Submission Form**

Instructions for respondents:

1. Check that you have all the relevant documents, including:
   * the relevant draft ITT document, including Schedule Two
   * the Alternative Commercial Proposals (ACP) guidance document
   * Pharmac’s standard terms
2. Please email the ACP to [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz) by the deadline outlined in the relevant draft ITT. Pharmac will not consider any ACPs received after this date.

***Respondent details***

1. Profile

|  |  |
| --- | --- |
| **Item** | **Detail** |
| **Full legal name:** |  |
| **Trading name (if different):** |  |
| **Physical address:** |  |
| **Postal address:** |  |
| **Registered office:** |  |
| **Business website:** |  |
| **Type of entity (legal status):** |  |
| **NZBN number:** |  |
| **Country of residence:** |  |
| **GST registration number:** |  |

1. Point of contact

|  |  |
| --- | --- |
| **Item** | **Detail** |
| **Contact person:** |  |
| **Position:** |  |
| **Phone number:** |  |
| **Mobile number:** |  |
| **Email address:** |  |

***Proposal details***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Item(s) from 2025/26 ITT:** | | | | | | | | |
| **Pharmaceutical (brand name)** | **Formulation** | **List price** | **Unit price** | **Pack Size** | **Lead time** | **Medsafe approval (Y/N)** | **Community/Hospital supply** | |
|  |  |  |  |  |  |  |  | |
|  |  |  |  |  |  |  |  | |
| **Other Pharmaceuticals** | | | | | | | | |
| **Pharmaceutical (brand name)** | **Formulation** | **List price** | **Unit price** | **Pack Size** | **Lead time** | **Medsafe approval (Y/N)** | **Community/Hospital supply** | **Schedule/ Options for Investment listing** |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

1. Proposal summary (description of the proposal, including any proposed rebates and/or other special terms):
2. Confirmation that there are no intellectual property barriers (including patent barriers) to supply this product for the proposed indications in New Zealand, with additional information if required:
3. Description of any available implementation support:

|  |
| --- |
|  |